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The complex effects of plant cannabinoids on human physiology is not yet fully
understood, but include a wide spectrum of effects on immune modulation. The
immune system and its inflammatory effector pathways are recently emerging as
possible causative factors in psychotic disorders. The present study aimed to
investigate whether self-administered Cannabis use was associated with changes in
circulating immune and neuroendocrine markers in schizophrenia (SCZ) and bipolar
disorder (BD) patients. A screening of 13 plasma markers reflecting different
inflammatory pathways was performed in SCZ (n = 401) and BD patients (n = 242)
after subdividing each group into Cannabis user and non-user subgroups. We found that
i) soluble gp130 (sgp130) concentrations were significantly elevated among Cannabis
users in the SCZ group (p = 0.002) after multiple testing correction, but not in BD. ii)
Nominally significant differences were observed in the levels of IL-1RA (p = 0.0059),
YKL40 (p = 0.0069), CatS (p = 0.013), sTNFR1 (p = 0.031), and BDNF (p = 0.020), where
these factors exhibited higher plasma levels in Cannabis user SCZ patients than in non-
users. iii) These differences in systemic levels were not reflected by altered mRNA
expression of genes encoding sgp130, IL-1RA, YKL40, CatS, sTNFR1, and BDNF in
whole blood. Our results show that Cannabis self-administration is associated with
markedly higher sgp130 levels in SCZ, but not in BD, and that this phenomenon is
independent of the modulation of peripheral immune cells. These findings warrant further
investigation into the potential IL-6 trans-signaling modulatory, anti-inflammatory,
neuroimmune, and biobehavioral-cognitive effects of Cannabis use in SCZ.
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The psychoactive and medicinal properties of the Cannabis
indica plant, a species of the genus Cannabis of Cannabaceae
family, have been recognized for millennia for its therapeutic
value in inflammation, pain, and rheumatic diseases (1). The
biologically active cannabinoids can be classified into two major
groups based on their psychotropic effect. The psychoactive
delta-9 tetrahydrocannabinol (D9-THC or THC) and the non-
psychoactive cannabidiol (CBD) are the two most widely studied
cannabinoids with potential therapeutic value. However, beyond
their effects on immunity and inflammation, cannabinoids have
also been shown to modulate neuronal development, as well as to
influence the general cytoarchitecture of the brain by regulating
axon and dendrite growth, synaptic dynamics, and pruning (2).
This latter phenomenon has recently been linked to their capacity
to increase the levels of neurotrophins in the mammalian CNS,
such as brain-derived neurotrophic factor (BDNF) (3, 4). It has
also been associated with potential adverse effects with regard to
cognition, behavior, respiratory, and cardiovascular disorders
(5, 6).
Schizophrenia (SCZ) and bipolar disorder (BD) are severe
mental illnesses which pose a substantial burden on the global
community by greatly affecting the mortality, life quality, and
costs of patient care (7). Although both have a strong genetic
component, details of their pathophysiology and etiology is not
yet known and the understanding of the underlying disease
mechanisms will expectedly be crucial for developing new and
effective therapies (8). The immune system and its inflammatory
effector pathways and elements are recently emerging as possible
contributing factors in psychotic disorders (9). Inflammatory
cytokines may alter brain functions in multiple ways, and can
pass the blood-brain-barrier through leaky regions or via passive
and active transport mechanisms. Abnormal immune activation
and dysregulated inflammatory responses have been suggested to
be involved in the pathophysiology of psychosis, and represent
potential underlying mechanisms in both SCZ and BD (10–12).
Plant cannabinoids have been shown to exert a wide spectrum of
effects on human immunity ranging from anti-inflammation to
neuroimmune modulation (13). THC and CBD are known to
have disparate influences on SCZ and BD symptoms, and
probably on their pathophysiology as well.
Despite the intensive research efforts in the past decades, the
complex effects of plant cannabinoids on human physiology,
including effects on the immune system, are not yet fully
understood, partly due to law regulations of plant-based
exocannabinoids in many countries. Since medical Cannabis
has already entered mainstream medicine, it is necessary for the
medical community to make efforts assessing the possible risks
and benefits of plant cannabinoids in order to provide reliable and
competent clinical care. In this study, we aimed to investigate the
effects of Cannabis consumption (users versus nonusers) on
circulating inflammatory, immune, and neuroendocrine markers
in SCZ and BD patients. The following biomarkers were selected
as they reflect different (sub)parts of the inflammatory network,
also because they are stable factors with relatively long biological
half-life that provide reliable information with regard to long-termFrontiers in Psychiatry | www.frontiersin.org 2changes in immune system responses: interleukin 1 receptor
antagonist (IL-1RA), soluble glycoprotein 130 (sgp130, the
natural inhibitor of soluble interleukin-6 receptor trans-
signaling responses), and soluble tumor necrosis factor receptor
1 (sTNFR1), which are general markers of inflammation; the
neutrophil markers myeloperoxidase (MPO) and cathepsin S
(CatS); YKL40 (also known as Chitinase-3-like protein 1 or
CHI3L1), which is a marker of monocyte/macrophage activation;
chemokine C-X-C motif ligand 16 (CXCL16), pentraxin 3 (PTX3),
osteoprotegerin (OPG), von Willebrand factor (vWF), and
activated cell adhesion molecule (ALCAM), which are markers of
vascular inflammation; Parkinson disease protein 7 (PARK7) and
BDNF, which are markers of neuroendocrine modulation in
various neuropsychiatric disorders. We and others have
previously shown that some of these markers are dysregulated in
psychosis (e.g., IL-1Ra, OPG, sTNFR1, vWf, and sgp130), while
some are related to neuroinflammation (e.g., CXCL16 and
ALCAM) and can be modulated by cannabinoids (4–6, 14–16).
The aim of this study is to investigate if self-administered Cannabis
use is associated with alterations in immune and neuroendocrine
plasma markers in SCZ and BD. Here, we report the modulatory
potential of Cannabis on circulating immune and neuroendocrine
markers in SCZ in a disease-specific manner.MATERIALS AND METHODS
Setting and Participants
The current study is part of the ongoing Thematically Organized
Psychosis (TOP) study, which includes participants from
hospitals in the Oslo region, Trondheim, and Southeast
regional hospitals in Norway. Information about recruitment
procedures, inclusion and exclusion criteria, and clinical
assessments for the TOP study as a whole have been described
in detail in previous reports (16, 17). All participants have given
written consent and the study was approved by the Norwegian
Scientific Ethical Committees and the Norwegian Data
Protection Agency. The authors assert that all procedures
contributing to this work comply with the ethical standards of
relevant guidelines and regulations.
Sample Characteristics
The primary study sample of the present work consisted of 242
bipolar disorder patients (BD; 164 type I, 66 type II, 12 not
otherwise specified) and 401 schizophrenia spectrum patients
(SCZ; 296 schizophrenia, 77 schizoaffective, 28 schizophreniform).
All participants underwent a clinical examination that included
diagnostic interviews based on Structured Clinical Interview in
DSM-IV axis I Disorders (SCID-1) and structured assessments of
clinical symptoms, BMI, use of psychotropic medication, smoking
habits, alcohol consumption, and illicit substance use. Diagnostic
evaluation was performed by trained psychologists and
psychiatrists, all of whom participated regularly in diagnostic
meetings supervised by professors in psychiatry. The main
inclusion criteria were confirmed diagnosis of either SCZ
spectrum disorder or BD according to the Diagnostic and
Statistical manual of Mental Disorders (DSM)-IV, age betweenJuly 2020 | Volume 11 | Article 642
Szabo et al. Sgp130 and Cannabis Use in Schizophrenia18 and 65, and ability to give informed written consent. The main
exclusion criteria were clinically significant brain injury, neurological
disorder, and any substance use other than Cannabis within the last
6 months prior to blood sampling. Patients with ongoing infection,
autoimmune disorders or cancer were also excluded. Cannabis was
self-administered in the user cohorts and “Cannabis use” was
defined as any use in the last 6 months prior to blood sampling.
Samples were subjected to high sensitivity plasma EIA and Illumina
microarray analyses. Substance use was documented through
interviews, urine samples, the Clinical Drug Use Scale (DUS) and
the Clinical Alcohol Use Scale (AUS) (18, 19). Substance use
disorders were diagnosed using the SCID-E module. All accessible
information in each case was examined to avoid false positive and
false negative substance users. The study sample also included 613
healthy controls (284 females, 329 males; mean age 33.4). Since
sufficient data on illegal drug use was not available for the controls,
they were not included in the statistical analyses, but they were used
to determine the average plasma concentrations in healthy subjects
for the examined biomarkers.Measurement of Inflammatory and
Neuroendocrine Markers in Plasma
Blood samples from both disease cohorts were obtained at Oslo
University Hospital (OUH) following the same standardized
procedures in accordance with the EUSTAR guidelines on
biobanking (20). Peripheral blood samples were collected in
EDTA tubes and were centrifuged at >2,100 g at room
temperature within 30 min. Plasma aliquots were then stored
at −80°C until assayed. Circulating YKL40, CatS, sTNFR1,
BDNF, sgp130, IL-1RA, Alcam, MPO, CXCL16, Park7, vWF,
OPG, and PTX3 levels were analyzed in duplicate using
commercially available antibodies (all from R&D Systems,
Minneapolis, MN, USA; except IL-1Ra, Peprotech, RockyHill,
NJ, USA) in a 384 format using a combination of a SELMA (Jena,
Germany) pipetting robot and a BioTek (Winooski, VT, USA)
dispenser/washer. Absorption was read at 450 nm with
wavelength correction set to 540 nm using an ELISA plate
reader (Bio-Rad, Hercules, CA, USA). Intra- and inter-assay
coefficients of variation were <10% for all EIAs.RNA Expression Analysis
Blood samples for mRNA expression measurements were
collected in Tempus Blood RNA Tubes (Life Technologies
Corporation). Total RNA was extracted with the TEMPUS 12-
Port RNA Isolation Kit (Applied Biosystems) and ABI PRISM
6100 Nucleic Acid PrepStation (Applied Biosystems) according to
the manufacturer’s protocol. Gene expression analysis of immune-
related genes was performed with Illumina HumanHT-12 v4
Expression BeadChip (Illumina, Inc.). Multidimensional scaling
and hierarchical clustering were used for regular quality control,
including sample quality measurements and removal of outliers, as
well as removal of multiple batch effects. This was followed by
log2-transformation. If more than one probe for a single gene were
available, only the constitutive probe targeting all gene transcriptsFrontiers in Psychiatry | www.frontiersin.org 3was used. In total, six mRNA probes targeting six Cannabis-
associated immune marker genes were examined. More details on
microarray pre-processing and quality control have previously
been reported (21).Statistical Analyses
Within each diagnostic category (BD and SCZ), patients were
divided into two groups based on whether they had used any
Cannabis within the last 6 months prior to blood sampling
(users) or not (non-users). To identify significant differences
between users and non-users in clinical metrics of interest,
Student’s two-sided t-test was used for numerical variables (the
Wilcoxon rank sum test was used for non-parametric variables)
and Pearson’s Chi-squared test was used for categorical variables.
To investigate whether plasma concentrations of inflammatory
and neuroendocrine biomarkers were related to Cannabis use
within each diagnostic group, separate multiple linear regression
analyses were performed for BD and SCZ. The predictor variable
was Cannabis status (non-user vs. user) and the response
variable was circulating immune marker concentrations. All
analyses were adjusted for sex, age, BMI, smoking status (yes/
no), alcohol consumption, and the use of four different types of
medication (antipsychotics, anticonvulsants, antidepressants,
and lithium). Medication doses were standardized prior to
analysis by converting them to Defined Daily Dosages (DDD)
in accordance with the guidelines from the World Health
Organization Collaborating Center for Drug Statistics
Methodology (https://www.whocc.no/). The Bonferroni
procedure was used to adjust the p-values for the number of
statistical tests performed. Because of the unbalanced design of
our datasets, we log2-transformed any immunological marker
with severely non-normal residuals or unequal variances
between groups. To examine whether Cannabis status was
associated with gene expression levels of the significant
inflammatory markers, a separate but partially overlapping
sample of 249 BD patients (180 type I, 54 type II, 15 not
otherwise specified) and 383 SCZ patients (270 schizophrenia,
78 schizoaffective, 35 schizophreniform) was used (Supplementary
Figure S2, Supplementary Table S1). The same statistical
procedures as described above were followed. All analyses were
performed in R 3.4.1.RESULTS
Demographic and clinical variables are summarized in Table 1. In
both diagnostic groups, age was strongly associated with Cannabis
use, and Cannabis users were on average 6.1 years younger than
non-users. Among SCZ patients, associations were also found
between Cannabis use and BMI (p = 6.54e-5), tobacco smoking
(p = 3.93e-9), alcohol consumption (p = 6.91e-7), and age of onset
of psychotic symptoms (1.34e-4). Interestingly, BD patients who
smoked Cannabis experienced less negative symptoms than patients
without recent Cannabis use (p = 0.009). In the SCZ group,
Cannabis use was associated with an increased risk of psychoticJuly 2020 | Volume 11 | Article 642
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literature (5, 15). There were no significant differences in the use of
antipsychotics, antiepileptics, or lithium in any of the disease
groups, but SCZ patients who smoked Cannabis used less
antidepressants than non-smokers (p = 0.027).
Significant Association Between Cannabis
Use and sgp130 Levels
We first compared the levels of 13 stable plasma biomarkers
involved in immune and neuroendocrine regulation (YKL40,
CatS, sTNFR1, BDNF, sgp130, IL-1RA, Alcam, MPO, CXCL16,
Park7, vWF, OPG, and PTX3) in the Cannabis user versus non-user
groups among BD and SCZ patients. The circulating levels of
sgp130 were significantly higher among Cannabis users in the
SCZ group after adjustment for the number of tests performed
(p = 0.002; Figure 1A, Table 2). The log2 mean difference was
0.175, which translates to an increase of 27.3 ng/ml (12.9%) in
absolute concentration. Non-user SCZ patients had a mean sgp130
level below the mean concentration found in healthy controls, but
this deficiency was completely reversed in the Cannabis group
(Figure 1A). Females had on average lower sgp130 levels than
males, and this difference was generally not affected by Cannabis
use, indicating that Cannabis had similar effects on sgp130 levels in
both genders. To further explore the nature of the sgp130
association in SCZ, patients were grouped according to the
severity of Cannabis use. However, no dose-dependent
relationship was found between Cannabis use and sgp130 (F(2,
42) = 0.44, p = 0.65), which could be explained by the lack of
detailed temporal resolution in the Cannabis data (Figure 1B).
Although tobacco smoking was strongly correlated with CannabisFrontiers in Psychiatry | www.frontiersin.org 4use, the duration and frequency of tobacco smoking did not have a
significant effect on sgp130 concentration (p = 0.75; Supplementary
Figure S1). No significant difference in sgp130 levels between users
and non-users was observed in the BD group (p = 0.87; Figure 1,
Table 2). All BD patients, independent of Cannabis status, had
suboptimal sgp130 levels comparable to the levels found in non-user
SCZ patients (Figure 1).
Nominally Significant Cannabis
Associations
In the SCZ group, nominally significant associations (i.e.,
associations that did not survive multiple testing correction)
were found between Cannabis exposure and five inflammatory
markers: IL-1RA (p = 0.0059), YKL40 (p = 0.0069), CatS (p =
0.013), sTNFR1 (p = 0.031), and the neurotrophin BDNF (p =
0.020; Figure 2, Table 2). Although Cannabis users had
increased levels of all five markers compared to non-users, IL-
1RA and BDNF levels were still below the average concentration
found in healthy controls. Females had generally higher levels of
IL-1RA and lower levels of CatS than males, while no gender
differences were seen for YKL40, BDNF, and sTNFR1 (Figure 2).
Associations Between Cannabis Use and
mRNA Expression
To examine if the observed changes in systemic markers could be
attributed to the modulation of circulating immune cells by
Cannabis exposure, we tested whether Cannabis status was also
associated with the mRNA expression levels of IL6ST, IL1RN,
CHI3LI, CTSS, BDNF, and TNFRSF1A genes encoding sgp130,
IL-1RA, YKL40, CatS, BDNF, and sTNFR1, respectively. NoTABLE 1 | Demographic and clinical characteristics of schizophrenia (SCZ) and bipolar disorder (BD) patients in the immune marker sample grouped according to
recent Cannabis use (User) or no recent Cannabis use (Non-user).
SCZ patients BD patients
Non-user User Non-user User
n = 341 n = 60 n = 205 n = 37
Mean SD Mean SD Test statistic p-value Mean SD Mean SD Test statistic p-value
Age 31.9 10.5 26.0 7.7 t = −5.18 1.15e-6** 35.5 12.6 29.2 9.3 t = −3.63 5.67e-4**
Sex, female (n, %) 161 47.2 16 26.7 c2 = 7.42 0.006* 125 61.0 18 48.6 c2 = 1.49 0.222
Education (years) 12.9 2.9 12.0 2.1 t = −2.75 0.007* 14.5 3.0 13.7 3.0 t = −1.41 0.165
BMI 27.0 5.6 24.5 3.7 t = −4.17 6.54e-5** 25.6 4.5 25.4 4.7 t = −0–31 0.756
Tobacco use, yes (n, %) 161 47.2 52 86.7 c2 = 34.66 3.93e-9** 100 48.8 26 70.3 c2 = 4.97 0.026*
Alcohol units 6 months (MD, range) 10 0–1456 65 0–1098 W = 5769.5 6.91e-7** 52 0–1820 117 2–2184 W = 2404.5 0.001*
Age of onset (years) 24.5 8.6 20.8 6.1 t = −3.96 1.35e-4** 22.8 9.9 21.4 7.7 t = −1.01 0.318
PANSS positive 15.2 5.4 17.1 5.3 t = 2.60 0.011* 10.2 3.9 11.7 4.1 t = 2.10 0.041*
PANSS negative 15.8 6.3 16.7 6.8 t = 0.90 0.372 10.4 3.8 9.0 2.7 t = −2.68 0.009*
PANS general 31.9 9.0 34.4 8.3 t = 2.04 0.044* 26.1 6.8 25.2 6.2 t = −0.72 0.477
PANSS total 63.0 17.2 68.1 17.5 t = 2.10 0.039* 46.6 11.9 45.4 10.6 t = −0.60 0.548
IDS 18.8 12.9 14.5 11.7 t = −1.88 0.068 16.1 11.5 16.0 12.0 t = −0.07 0.946
YMRS 5.1 5.0 6.3 5.6 t = 1.33 0.189 3.7 5.1 4.5 5.1 t = 0.87 0.387
GAF Symptoms 42.7 11.3 40.1 12.1 t = −1.54 0.127 56.6 12.5 56.2 10.1 t = −0.19 0.846
GAF Function 43.7 11.0 40.2 9.8 t = −2.48 0.015* 53.2 12.7 53.0 11.8 t = −0.09 0.925
Antipsychotics (DDD) 1.23 1.22 1.44 0.99 t = 1.47 0.146 0.53 0.76 0.34 0.50 t = −1.90 0.061
Anticonvulsants (DDD) 0.084 0.26 0.057 0.24 t = −0.79 0.432 0.32 0.52 0.24 0.41 t = −1.09 0.282
Antidepressants (DDD) 0.47 0.85 0.28 0.55 t = −2.24 0.027* 0.51 0.89 0.42 0.78 t = −0.66 0.509
Lithium (DDD) 0.026 0.18 0.017 0.13 t = −0.48 0.630 0.24 0.50 0.20 0.46 t = −0.52 0.604July 2020 | Volume 11 | A**p < 0.001, *p < 0.05. BMI, Body Mass Index; PANSS, Positive and Negative Syndrome Scale; IDS, Inventory of Depression Scale; YMRS, Young Mania Rating Scale; GAF, Global
Assessment of Functioning; MD, Median; DDD, Defined Daily Dose.rticle 642
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SCZ patients (Supplementary Figure S3; Supplementary Table
S2). Neither did we find any significant associations for mRNA
expression of the rest of the genes of our screening platform
(MPO, YKL40, CXCL16, PTX3, OPG, vWF, ALCAM, and
PARK7) in our patient cohorts (data not shown).DISCUSSION
The aim of the present study was to investigate whether self-
administered Cannabis use was associated with changes inFrontiers in Psychiatry | www.frontiersin.org 5circulating immune and neuroendocrine markers in SCZ and
BD. We performed a neuroimmune screening of 13 plasma
markers in SCZ and BD patients, subdividing each group into
Cannabis user and non-user subgroups. We found that sgp130
concentrations were markedly elevated among Cannabis users in
the SCZ but not in the BD group. We also found indications of
increased levels of IL-1RA, YKL40, CatS, sTNFR1, and BDNF
among Cannabis using SCZ patients, but these differences were
not significant after Bonferroni correction. These results may
therefore reflect individual differences in Cannabis-related
inflammatory functions (IL-1RA, YKL40, CatS, and sTNFR1)
within and between the sample groups rather than being SCZ orA
B
FIGURE 1 | Effect of Cannabis use on soluble gp130 levels in bipolar disorder and schizophrenia patients, and associations between frequency of Cannabis use
and sgp130 levels in BD and SCZ. (A) Cannabis use was significantly associated with increased levels of soluble gp130 in schizophrenia (SCZ) but not in bipolar
disorder (BD) patients. The dotted lines represent the mean plasma level of gp130 in healthy controls (n = 613). The average gp130 level in BD patients, in both
Cannabis users and non-users, and in non-user SCZ patients was below the average level found in healthy controls. However, SCZ patients who have used
Cannabis had an elevated gp130 level above the level for healthy controls. As the dot plots indicate, Cannabis use had a comparable up-regulating effect in both
males and females. **Bonferroni-adjusted p-value < 0.01. (B) Patterns of Cannabis use during the last 6 months before blood sampling were assessed with the
Clinician Drug Use Scale (CDUS). No significant difference in sgp130 concentration was found between the different subgroups of Cannabis users in the SCZ group
(F(2,42) = 0.44, p = 0.65). The lack of a dose-response relationship between Cannabis exposure and sgp130 concentration may be due to the lack of detailed
temporal resolution in the Cannabis data. Since sgp130 levels are expected to depend on the time interval that has passed since the last exposure to Cannabis, the
inability to account for temporal differences may mask the dose-dependent effect of Cannabis on sgp130 concentrations.July 2020 | Volume 11 | Article 642
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cannabinoids THC and CBD have recently been shown to
increase the levels of neurotrophins in the mammalian CNS
including BDNF, and thus can contribute to increased
neuroplasticity and improved cognitive performance (3, 4).
Our results corroborate these findings and suggest a potential
neurotrophin modulating effect of Cannabis in SCZ.
Changes in the plasma concentrations of sgp130, IL-1RA,
YKL40, CatS, sTNFR1, and BDNF were not accompanied by
corresponding changes at the gene expression level in whole
blood samples indicating limited contribution from peripheral
immune cell modulation, but could potentially reflect the
involvement of other tissues, such as the liver, vascular
endothelium, or glial cells.
The critical importance of the regulation of IL-6 trans-signaling
through the blood-brain-barrier has been demonstrated in central
nervous system inflammation, as well as in neurodegenerative and
neuropsychiatric disorders, such as Alzheimer’s and Parkinson’s
[reviewed in (22, 23)]. The regulatory effect of gp130 on
inflammation is tightly linked to the pleiotropic nature of the IL-6
system in mammals. Gp130, which exists in both a membrane-
bound form (gp130) and in a soluble form (sgp130), is a common
signal-transducing subunit of several cytokine receptors involved in
inflammation and immunity including but not limited to IL-6 (24).
Although IL-6 can be produced by several immune and non-
immune cells, its receptor (IL-6R) expression is restricted to only
a subset of cells, such as certain lymphocytes (25), microglia (26),
and hepatocytes (27). IL-6R also exists in a soluble form (sIL-6R)
produced via alternative splicing or limited proteolysis (23).
Signaling of the IL-6/IL-6R complex requires the cell membrane-
bound form of the co-receptor gp130. Binding of the complex to
gp130 initiates downstream signaling targeting JAK2/STAT3, PI3
kinase, ERK, and other intracellular effector pathways (28). IL-6 canFrontiers in Psychiatry | www.frontiersin.org 6modulate cellular functions in two different ways (Figure 3): In
classical signaling, IL-6 binds to IL-6R and then the complex
triggers the dimerization of membrane-gp130 leading to
downstream effects that are pivotal in the regulation of anti-
inflammatory signals (29). In IL-6 trans-signaling, IL-6 is bound
by sIL-6R and the complex can activate distant cells expressing
membrane-bound gp130 in a paracrine and endocrine manner
which is dominantly pro-inflammatory (23). Gp130 signaling is also
involved in neuronal and astrocyte differentiation and survival (30),
and in the astrocytic control of CNS neurotoxic inflammation
(31, 32).
Soluble gp130 is a decoy receptor that is produced under
physiological conditions and is able to bind the IL-6/sIL-6R
complex and thereby potently and selectively blocking
inflammatory trans-signaling (Figure 3) (28, 33). Thus, it can
alleviate the harmful in vivo effects of IL-6 in the CNS (34). Indeed,
sgp130 has been shown to exert strong anti-inflammatory effects
in both local and systemic contexts (22, 23, 34, 35), and to protect
from the effects of lipopolysaccharide (LPS)-induced sickness
behavior in a murine model accompanied by dramatic decrease
in IL-6 mRNA and protein levels in the hippocampus (35).
In accordance with the immune hypothesis of SCZ, dysregulated
and/or low-grade chronic brain inflammation may interfere with
cognition, mood regulation, and higher-order functioning, and any
means of modulating this “inflammatory immune-brain” cross-talk
may pose a potential therapeutic target (11, 12). In a recent study,
sgp130 levels were found to be lower in SCZ and BD patients than in
healthy controls (10). We hypothesize that Cannabis consumption
may contribute to elevated levels of sgp130 in SCZ patients favoring
a systemic anti-inflammatory milieu. This effect may be more
pronounced if it is also accompanied by mild increase in the
levels of the anti-inflammatory regulators IL-1RA and sTNFR1.
Supportive of this idea, a recent report revealed that Cannabis useTABLE 2 | Associations between inflammatory and neuroendocrine markers in plasma and Cannabis use in schizophrenia and bipolar disorder patients.
Immune
marker
SCZ patients BD patients










Mean SD Mean SD
sgp130 1.62e-4** 2.11e-3 7.724 0.067 7.899 0.063 0.866 1.000 7.712 0.081 7.712 0.079
IL-1RA 5.91e-3* 0.077 7.783 0.424 8.241 0.304 0.255 1.000 7.711 0.500 7.285 0.572
YKL40 6.93e-3* 0.090 5.231 0.236 5.480 0.178 0.279 1.000 5.395 0.404 5.341 0.324
CatS 0.013* 0.165 2.346 0.216 2.496 0.195 0.392 1.000 2.276 0.157 2.307 0.149
BDNF 0.020* 0.255 2.230 0.174 2.534 0.142 0.259 1.000 2.254 0.181 2.072 0.197
sTNFR1 0.031* 0.400 0.839 0.240 0.984 0.127 0.145 1.000 0.831 0.176 0.882 0.197
Park7 0.182 1.000 2.314 0.196 2.201 0.154 0.947 1.000 2.131 0.000 2.111 0.208
MPO 0.247 1.000 8.020 0.190 8.280 0.190 0.418 1.000 8.201 0.382 7.827 0.407
Alcam 0.327 1.000 38.619 2.694 38.205 2.104 0.756 1.000 38.880 2.224 37.160 2.454
vWF 0.379 1.000 6.335 0.226 6.214 0.167 0.352 1.000 6.126 0.308 6.356 0.348
OPG 0.400 1.000 0.420 0.112 0.418 0.085 0.082 1.000 0.485 0.148 0.305 0.156
PTX 0.500 1.000 1.576 0.250 1.833 0.205 0.600 1.000 1.530 0.238 1.476 0.222
CXCL16 0.701 1.000 4.060 0.162 4.099 0.150 0.059 0.769 3.972 0.156 4.156 0.121July 2020 | Volume 11 | Artic**Significantly associated after Bonferroni correction at ⍺ = 0.05. *Nominally associated at p < 0.05. The means and standard deviations (SD) shown are for the fitted values from the full
regression model.le 642
Szabo et al. Sgp130 and Cannabis Use in Schizophreniadisorder is associated with decreased risk of diseases of gut-brain
interaction and inflammatory bowel disease in SCZ, but not in
healthy controls (36). Since circulating inflammatory biomarker
levels are inversely correlated with negative symptom severity in
SCZ (11, 12), the documented anti-inflammatory effect of Cannabis
may stand in the background of the observed associations between
Cannabis consumption and improved mood regulation.
The observed sgp130-modulating effect of Cannabis in SCZ
may be due to its immunoregulatory potential, especially its effect
on IL-6 signaling and presumably on IL-6 trans-signaling
feedback-loops as suggested by others (13). The beneficial effects
of Cannabis consumption in people with SCZ (“Cannabis self-
medication hypothesis”) could be attributed to CBD, its natural
anti-inflammatory and antipsychotic component, which hasFrontiers in Psychiatry | www.frontiersin.org 7recently been reported to be clinically effective in the adjunctive
therapy of SCZ (37, 38). Due to its observational nature, our study
does not establish a causal link between Cannabis use and
symptom severity or cognitive performance in SCZ, but may
reveal a disease-specific phenomenon that is not present in BD.
Additionally, the lack of temporal resolution with regard to our
Cannabis data (i.e., the lack of control of timing relative to last
Cannabis use) poses a major limitation to this study. Blood
concentrations of the identified immune markers are expected
to be affected by both the frequency and amount of Cannabis use,
as well as the time span that has elapsed since last exposure. The
fact that temporal differences were not accounted for, could
explain why we did not see a dose-dependent relationship
between sgp130 levels and Cannabis use after stratification byA B
C D
E
FIGURE 2 | Nominally significant associations between Cannabis use and inflammatory and neuroendocrine markers (A–E). Cannabis use had a nominally
significant association (at p < 0.05) with five immune and neuroendocrine markers in SCZ but not in BD patients. All markers had higher plasma levels in Cannabis
users than in non-users. The dotted lines represent the average concentration in healthy controls (n = 613). *Nominal p-value < 0.05.July 2020 | Volume 11 | Article 642
Szabo et al. Sgp130 and Cannabis Use in Schizophreniaseverity of use (use without disabilities, abuse, and addicted).
Therefore, although our findings suggest an anti-inflammatory
effect of sgp130 that may contribute to the therapeutic value of
Cannabis in SCZ, elucidation of the physiological details requires
future investigations, preferably by comparing sgp130 levels
directly with urine concentrations of cannabinoids and their
metabolites in SCZ and BD patients.
The absence of the inflammation-modulatory phenomenon of
Cannabis in BDmay resonate with earlier reports on the neutral or
potentially adverse effects of Cannabis use on BD symptoms and
disease evolution (39, 40). Furthermore, we speculate that our
findings regarding the effect of Cannabis self-administration on
circulating immune marker levels likely reflect the relatively high
CBD content of available Cannabis products in the streets of
Norway (41). On the other hand, the impact of the psychotropic
cannabinoid THC on human brain functions has been highly
controversial. It is important to note that, despite its general anti-
inflammatory effect, exposure to THC, particularly during
adolescence, is hypothesized to perturb the neuroendocrine-
immune homeostasis evoking latent vulnerability to psychosis or
exacerbate symptoms in individuals with SCZ (42–44). In
agreement with this, a recent GWAS study involving a large
cohort of lifetime Cannabis users revealed causal positive
influence between Cannabis use and SCZ risk (45). Thus, while
medical Cannabis and cannabinoids are emerging as potential
therapeutic adjuvants in neuropsychiatric disorders and other
diseases, it is very important to make efforts estimating the
possible risks and benefits of cannabinoids in order to provide
reliable and competent clinical care.Frontiers in Psychiatry | www.frontiersin.org 8Taken together, our results show for the first time that
Cannabis self-administration is associated with elevated levels
of sgp130 and several other immune and neuroendocrine
markers in SCZ, but not in BD, and that this phenomenon is
independent of the modulation of peripheral immune cells.
These findings warrant further investigation into the potential
neuroimmune, anti-inflammatory, and biobehavioral-cognitive
effects of Cannabis use in SCZ.DATA AVAILABILITY STATEMENT
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